Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?

To: H James Morris who wrote (118241)	2/20/2001 10:59:05 PM
From: Mark Fowler	Respond to of 164685

Mark, what's your point? Billy is the one with tech up to his ass...tell him not me. BTW<< DEFENSE: President Bush Focuses on Defense (Feb. 12, 2001) Lobbying by Donald Rumsfeld, military commanders and congressional hawks may have produced a reversal of Bush's go-slow directive on Pentagon spending hikes. WRG's Gen. David E. Baker (Ret.) says the focus now is on the Pentagon's sweeping review of strategy, structure and missions; systems that are "light, stealthy, lethal and hard to attack" will be favored. This review has been put on a very fast track in the last few days and we think Rumsfeld is going to move the process forward as quickly as possible. Says Baker: "The results of the Pentagon review should give investors visibility into what programs have increased risk, but we believe the outlook for the sector remains positive. We expect Congress will be a full partner in the formulation of the budget for the Department of Defense and forecast bipartisan support for modernization efforts that may lead to multi-year, multi-billion dollar contracts for companies in the sector."

To: H James Morris who wrote (118241)	2/20/2001 11:01:10 PM
From: Mark Fowler	Respond to of 164685

HEALTH CARE: Bush Is Likely to Stop Slowdown in Drug Approvals (Feb. 16, 2001) The slowdown in the pace of approvals of new drugs at the Food and Drug Administration (FDA) is unlikely to worsen, report WRG's Eric Weissenstein and Paul Heldman. "The FDA is clearly spooked by a spate of prescription drug withdrawals from the U.S. market due to safety concerns," say Weissenstein and Heldman. "But we think the agency has not abandoned its commitment to faster drug approvals catalyzed by the 1992 drug user fee law." Improvement in approval times depends, in part, on whom the Bush Administration appoints to run the FDA.